


Amendments to the Claims:



This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A composition for inhibiting the secretion of IgE-dependent histamine-releasing factor (HRF), which contains a benzimidazolic compound having proton pump inhibitor activity, as an active ingredient.

2. (Original) The composition of Claim 1, wherein the benzimidazolic compound is a lipid-soluble weak base consisting of a benzimidazole ring, a pyridine ring and a methylsulfinyl group located between them, and has a structure represented by the following formula:



wherein Het¹ is  ; Het² is  ; R¹ and R²

which may be the same or different, each independently represents

hydrogen, methoxy, or difluoromethoxy; R³ represents hydrogen or sodium; and R⁴, R⁵ and R⁶, which may be the same or different, each independently represents hydrogen, methyl, methoxy, methoxypropoxy, or trifluoroethoxy.

3. (Original) The composition of Claim 2, wherein the benzimidazolic compound is one or more selected from the group consisting of omeprazole, lansoprazole, pantoprazole, rabeprazole, and derivatives and isomers thereof.

4. (Original) The composition of Claim 3, which additionally contains at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, which all have proton pump inhibitor activity.

5. (Currently Amended) The composition of Claim 1 ~~any of Claims 1 to 4~~, which is used for the prevention and treatment of various allergic diseases caused by HRF, including asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

6. (Original) The composition of Claim 5, which is used for the prevention and treatment of asthma, urticaria, allergic bronchiectasis, and atopic dermatitis.

7. (Original) The composition of Claim 5, which is used for the prevention and treatment of anaphylaxis, allergic rhinitis, and hay fever.

8. (Original) The composition of Claim 5, which is used for the prevention and treatment of malaria.

9. (Original) A composition for inhibiting the secretion of HRF, which contains, as a single active ingredient, at least one substance selected from the group consisting of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, and macrolide antibiotic bafilomycin and concanamycin, which all have proton pump inhibitor activity.

10. (Original) The composition of Claim 9, which is used for the prevention and treatment of various allergic diseases caused by HRF, including asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

11. (Original) The composition of Claim 10, which is used for the prevention and treatment of asthma, urticaria, allergic bronchiectasis, and atopic dermatitis.

12. (Original) The composition of Claim 10, which is used for the prevention and treatment of anaphylaxis, allergic rhinitis, and hay fever.

13. (Original) The composition of Claim 10, which is used for the prevention and treatment of malaria.

14. (New) The composition of Claim 2, which is used for the prevention and treatment of various allergic diseases caused by HRF, including asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

15. (New) The composition of Claim 3, which is used for the prevention and treatment of various allergic diseases caused by HRF, including asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

16. (New) The composition of Claim 4, which is used for the prevention and treatment of various allergic diseases caused by HRF, including asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.